Company intelligence / Profile preview

DRIVE

Atlanta, Georgia, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

DRIVE has successfully advanced multiple antiviral candidates from discovery through preclinical and into clinical stages. Its most notable achievement is the development of EIDD‑2801 (molnupiravir), which was rapidly moved into human testing for COVID‑19 in partnership with Ridgeback Biotherapeutics. The company’s leadership team has a track record of bringing several FDA-approved antivirals to market.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

Ridgeback Biotherapeutics LP

Beyond the preview

Go deeper on DRIVE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DRIVE.

Explore the full profile